medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 1

<< Back Next >>

Gac Med Mex 2016; 152 (1)

Hyperleptinemia associated with ischemic stroke

García-Sánchez JL, Jiménez-Saab NG, Guerrero-González J, Elizalde-Barrera CI, Reyna-Ramírez MJ, Rubio-Sánchez ME, Ledesma-Velázquez A, Montaño-Alonso EA

Language: Spanish
References: 15
Page: 78-86
PDF size: 99.46 Kb.


ABSTRACT

Introduction: The major risk factors for stroke are obesity, diabetes mellitus, systemic arterial hypertension (SAH) and dyslipidemia. In 1994 leptin was identifies as adipokine produced by adipose tissue. Its main action is the regulation of energy balance. Currently, hyperleptinemia is associated with cardiovascular disease. Objective: To determine the association between serum leptin and stroke in patients with SAH. Methods: We determined serum leptin in subjects with stroke and SAH, and compared this with patients with SAH without stroke. We calculated Student t, χ2 , and odds ratio (OR) for quantitative and qualitative variables. Results: 60 subjects were recruited, 30 subjects per group. Considering a value › 3.93 ng/ml as hyperleptinemia, it also was found a t = 2.8 (p = 0.007), and χ2 with one degree of freedom of 10.82 (p = 0.001), obtaining an OR of 3.05 for the development of stroke in the presence of elevated leptin (95% CI: 0.9-9.6; p = 0.05). Conclusions: Hyperleptinemia is more common in patients with stroke than in those without this condition. But the question remains whether hyperleptinemia is a stroke risk factor or protective factor


REFERENCES

  1. Cabrera A, Martínez O, Laguna G, et al. Epidemiología de la enfermedad vascular cerebral en hospitales de la Ciudad de México. Estudio multicéntrico. Med Int Mex. 2008;24(2):98-103.

  2. Longo D, Kasper D, Jameson J, Fauci A, Hauser S, Joseph L. Harrison’s Principles of Internal Medicine. Cap. 370: Cerebrovascular Diseases. 18.a ed. EE.UU.: McGraw Hill; 2012.

  3. Barquera S, Campos-Nonato I, Rojas R, Rivera J. [Obesity in Mexico: epidemiology and health policies for its control and prevention]. Gac Med Mex. 2010;146(6):397-407.

  4. Goldstein L, Adams R, Alberts M, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Stroke. 2006;37(6):1583-633.

  5. Auwerx J, Staels B. Leptin. Lancet. 1998;351(9104):737-42.

  6. Pisabarro R, Irrazábal E, Recalde A, et al. Leptina: una hormona secretada por el tejido adiposo. Primer estudio en muestra poblacional uruguaya. Rev Med Uruguay. 1999;15:43-8.

  7. Khan SM, Hamnvik OP, Brinkoetter M, Mantzoros CS. Leptin as a modulator of neuroendocrine function in humans. Yonsei Med J. 2012;53(4):671-9.

  8. Li WC, Hsiao KY, Chen IC, Chang YC, Wang SH, Wu KH. Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol. 2011;10:36.

  9. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the US population. Am J Cardiol. 2007;100(2):234-9.

  10. Savoia C, Schiffrin EL. Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Med Clin North Am. 2004;88(1):39-62.

  11. McMahon M, Skaggs B, Sahakian L, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis. 2011;70(9):1619-24.

  12. Liu J, Butler KR, Buxbaum SG, Hye-Sung J, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxf). 2010;72(1):32-7.

  13. García N, Sánchez M, Galván R, Mendoza V. Hipercolesterolemia, hipertrigliceridemia y resistencia a la insulina como factores de riesgo de diabetes mellitus tipo 2 en adultos mayores con hiperleptinemia. Artemisa en línea. México. 2006;31:114.

  14. Rosado J, Sánchez M, Galván R, Mendoza V. Relación de la resistencia a la insulina con los niveles séricos de leptina, adiponectina, IL-6 y factor de necrosis tumoral α en sujetos con diabetes mellitus tipo 2. Artemisa en línea. México. 2006;31:115.

  15. American Diabetes Association. Standars of Medical Care in Diabetes- 2013. Diabetes Care. 2013;36 Suppl 1.




2020     |     www.medigraphic.com